A. Anthoney

发表

Relationship between clinical efficacy and AEs of IMCgp100, a novel bispecific TCR–anti-CD3, in patients with advanced melanoma.

M. Sznol, A. Shoushtari, J. Infante, 2019, Journal of Clinical Oncology.

Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial

D. Cunningham, A. Maraveyas, J. Bridgewater, 2018, British Journal of Cancer.

Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial.

John R. Mackey, Fiona Campbell, David Goldstein, 2014, Journal of the National Cancer Institute.

Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial.

J. Šufliarský, P. Rutkowski, M. Debiec‐Rychter, 2017, European journal of cancer.

Vaccination of Colorectal Cancer Patients with Modified Vaccinia Ankara Encoding the Tumor Antigen 5T4 (TroVax) Given Alongside Chemotherapy Induces Potent Immune Responses

N. Habib, J. Nicholls, M. Carroll, 2007, Clinical Cancer Research.

A Critical Appraisal of the Role of Neoadjuvant Chemotherapy for Colorectal Liver Metastases: A Case-Controlled Study

H. Malik, A. Anthoney, G. Toogood, 2007, Annals of Surgical Oncology.

Synthesis of Recommendations From 25 Countries and 31 Oncology Societies: How to Navigate Through Covid-19 Labyrinth

Lazar Popovic, A. Valachis, K. Kamposioras, 2020, Frontiers in Oncology.

Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours

Jie Yang, Jih-Hsiang Lee, N. Strelkowa, 2020, British Journal of Cancer.

Impact of margin status on survival following pancreatoduodenectomy for cancer: the Leeds Pathology Protocol (LEEPP).

C. Verbeke, K. Menon, D. Gomez, 2009, HPB : the official journal of the International Hepato Pancreato Biliary Association.

Markers of tumor inflammation as prognostic factors for overall survival in patients with advanced pancreatic cancer receiving first-line FOLFIRINOX chemotherapy

A. Lamarca, J. Valle, K. Kamposioras, 2022, Acta oncologica.

Pancreaticobiliary Malignancies in the Emergency Room: Management of Acute Complications and Oncological Emergencies

A. Lamarca, K. Kamposioras, K. Papadimitriou, 2021, Journal of Gastrointestinal Cancer.

Solitary myocardial metastasis from small-bowel neuroendocrine carcinoma.

D. Treanor, A. Scarsbrook, C. Patel, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of intrapancreatic or extrapancreatic bile duct involvement on survival following pancreatoduodenectomy for common bile duct cancer

C. Verbeke, K. Kamposioras, A. Anthoney, 2014, The British journal of surgery.

Complications of systemic therapy--gut infections and acute diarrhoea.

A. Anthoney, Daniel L. Y. Lee, 2014, Clinical medicine.

Capecitabine and streptozocin +/- cisplatin for gastroenteropancreatic neuroendocrine tumours: predictors of long-term survival in the NET01 trial.

T. Meyer, D. Talbot, D. Cunningham, 2016 .

Targeting Carcinoembryonic Antigen with DNA Vaccination: On-Target Adverse Events Link with Immunologic and Clinical Outcomes

S. Halford, U. Şahin, D. Jodrell, 2016, Clinical Cancer Research.

Targeting Carcinoembryonic Antigen with DNA Vaccination: On-Target Adverse Events Link with Immunological and Clinical Outcomes Running Title: Anti-CEA DNA Fusion Vaccination

S. Halford, U. Şahin, D. Jodrell, 2016 .

A randomised phase II trial and feasibility study of palliative chemotherapy in frail or elderly patients with advanced gastroesophageal cancer (321GO)

K. Last, M. Jones, P. Hall, 2017, British Journal of Cancer.

ABC-06 | A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) che

A. Maraveyas, J. Bridgewater, P. Ross, 2019, Journal of Clinical Oncology.

Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma

D. Tuveson, J. Bridgewater, D. Jodrell, 2020, British Journal of Cancer.

Improving the outcome of salvage treatment for non-seminomatous germ cell tumours (NSGCT)

J. Bono, S. Kaye, J. Graham, 2000, British Journal of Cancer.

Results of a phase II study to evaluate the biological effects of intratumoral (ITu) reolysin in combination with low dose radiotherapy (RT) in patients (Pts) with advanced cancers.

A. Melcher, K. Harrington, C. Nutting, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

MMP-10 is overexpressed, proteolytically active, and a potential target for therapeutic intervention in human lung carcinomas.

M. Bibby, P. Loadman, A. Mearns, 2004, Neoplasia.

Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.

D. Cunningham, A. Maraveyas, J. Bridgewater, 2010, The New England journal of medicine.

Pancreaticobiliary Malignancies in the Emergency Room: Management of Acute Complications and Oncological Emergencies

A. Lamarca, K. Kamposioras, K. Papadimitriou, 2021, Journal of Gastrointestinal Cancer.

Second-line FOLFOX chemotherapy for advanced biliary tract cancer - Authors' reply.

W. Ryder, A. Maraveyas, J. Bridgewater, 2021, The Lancet. Oncology.

C-1311, a novel inhibitor of FLT3 and topoisomerase II: A phase 1 trial of a once every three week schedule in patients with advanced solid tumors

C. Twelves, A. Lundberg, Anne L. Thomas, 2008 .

Evaluation of the safety of C-1311 administered in a phase 1 dose-escalation trial as a 1-hour infusion once every 3 weeks in patients with advanced solid tumors.

P. Loadman, C. Twelves, A. Anthoney, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Neoadjuvant Intravenous Oncolytic Vaccinia Virus Therapy Promotes Anticancer Immunity in Patients

A. Melcher, R. Vile, H. Pandha, 2022, Cancer immunology research.

Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 ‘CREATE’

J. Blay, S. Aamdal, R. Sciot, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma

M. Sznol, A. Shoushtari, J. Infante, 2020, Clinical Cancer Research.

First-in-Human Study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics, and Pharmacodynamics, in Patients with Metastatic Cancer

U. Banerji, J. Spicer, D. Josephs, 2014, Clinical Cancer Research.

Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial

W. Ryder, A. Maraveyas, J. Bridgewater, 2021, The Lancet. Oncology.

Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial

M. Büchler, J. Neoptolemos, J. Izbicki, 2017, The Lancet.

Prognostic significance and therapeutic implications of Caveolin-1 in gastrointestinal tract malignancies.

K. Kamposioras, D. Mauri, A. Anthoney, 2021, Pharmacology & therapeutics.

Cisplatin and Adriamycin Resistance Are Associated with MutLα and Mismatch Repair Deficiency in an Ovarian Tumor Cell Line*

P. Modrich, P Modrich, A. Anthoney, 1996, The Journal of Biological Chemistry.

The Prognostic Significance of the Hedgehog Signaling Pathway in Colorectal Cancer.

K. Dimas, V. Papadopoulos, K. Kamposioras, 2016, Clinical colorectal cancer.

Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial.

T. Hickish, W. Greenhalf, Eithne Costello, 2014, The Lancet. Oncology.

ESPAC-4: A multicenter, international, open label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP), versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma

M. Büchler, J. Neoptolemos, J. Izbicki, 2016 .

Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial.

M. Büchler, J. Neoptolemos, M. Lerch, 2012, JAMA.

An EORTC phase I study of Bortezomib in combination with oxaliplatin, leucovorin and 5-fluorouracil in patients with advanced colorectal cancer.

D. Lacombe, F. Caponigro, S. Marréaud, 2009, European journal of cancer.

A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine

R. Plummer, C. Twelves, T. Evans, 2019, British Journal of Cancer.

NET-02: A multicenter, randomized, phase II trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients (pts) with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC).

J. Cave, Rohini Sharma, A. Lamarca, 2022, Journal of Clinical Oncology.

Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 ‘CREATE’

J. Blay, L. Collette, R. Sciot, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase I study of ZD0473 combined with paclitaxel for the treatment of solid malignancies

U. Gatzemeier, S. Kaye, C. Twelves, 2003, Cancer Chemotherapy and Pharmacology.

Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'.

L. Collette, R. Sciot, J. Šufliarský, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours.

J. Sludden, Y. Drew, D. Jamieson, 2016, European journal of cancer.

A Phase I pharmacokinetic and pharmacodynamic study of the oral MEK inhibitor , WX-554 , in patients with advanced solid tumours

Vicky, J. Sludden, Y. Drew, 2016 .

Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study – The UK ABC-01 Study

M. Highley, T. Meyer, A. Maraveyas, 2009, British Journal of Cancer.

Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study.

M. Büchler, J. Neoptolemos, J. Izbicki, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Redefining the R1 resection in pancreatic cancer

M. Mcmahon, P. Guillou, C. Verbeke, 2006, The British journal of surgery.

Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'.

L. Collette, R. Sciot, J. Šufliarský, 2019 .

The Role of Continuing Perioperative Chemotherapy Post Surgery in Patients with Esophageal or Gastroesophageal Junction Adenocarcinoma: a Multicenter Cohort Study

K. Kamposioras, J. Weaver, G. Papaxoinis, 2019, Journal of Gastrointestinal Surgery.

Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer

M. Büchler, J. Mackey, W. Greenhalf, 2018, British Journal of Cancer.

Predictive factors of thromboembolic complications in patients with esophagogatric adenocarcinoma undergoing preoperative chemotherapy

K. Kamposioras, J. Weaver, G. Papaxoinis, 2018, Acta oncologica.

Activity and safety of crizotinib in patients with advanced, metastatic alveolar soft part sarcoma (ASPS) with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase 2 trial 90101 CREATE.

J. Blay, S. Aamdal, A. Italiano, 2018 .

The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma

J. Kleeff, M. Büchler, J. Neoptolemos, 2017, Annals of surgery.

Clinical Grade OK432-activated Dendritic Cells: In Vitro Characterization and Tracking During Intralymphatic Delivery

A. Dietz, A. Melcher, C. Twelves, 2009, Journal of immunotherapy.

Pharmacodynamic effect of IMCgp100 (TCR–CD3 bispecific) on peripheral cytokines and association with overall survival in patients with advanced melanoma.

M. Sznol, A. Shoushtari, J. Infante, 2019, Journal of Clinical Oncology.

Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer

J. Mackey, W. Greenhalf, J. Neoptolemos, 2018, British Journal of Cancer.

Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial.

M. Büchler, J. Neoptolemos, J. Izbicki, 2019, JAMA surgery.

Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapy

M. Büchler, J. Mackey, W. Greenhalf, 2018, British Journal of Cancer.

'Tablet burden' in patients with metastatic breast cancer.

C. Twelves, M. Milić, A. Anthoney, 2016, European journal of cancer.

Hypoxia-Selective Targeting by the Bioreductive Prodrug AQ4N in Patients with Solid Tumors: Results of a Phase I Study

P. Jones, M. Albertella, P. Loadman, 2008, Clinical Cancer Research.

Quality of life, long-term survivors and long-term outcome from the ABC-02 study

D. Cunningham, A. Maraveyas, J. Bridgewater, 2016, British Journal of Cancer.

The Association of a Panel of Biomarkers with the Presence and Severity of Carcinoid Heart Disease: A Cross-Sectional Study

K. George, B. Keevil, G. Poston, 2013, PloS one.

Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours.

J. Wanders, J. Beijnen, J. Smyth, 2003, European journal of cancer.

Silencing of caveolin-1 in fibroblasts as opposed to epithelial tumor cells results in increased tumor growth rate and chemoresistance in a human pancreatic cancer model

G. Vassilopoulos, K. Dimas, C. Verbeke, 2018, International journal of oncology.

A phase I/II first-in-human trial of oral SRA737 (a Chk1 inhibitor) given in combination with low-dose gemcitabine in subjects with advanced cancer.

Y. Drew, A. Navarro, U. Banerji, 2019, Journal of Clinical Oncology.

hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA

J. Mackey, M. Büchler, W. Greenhalf, 2021, Cancers.

Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): a phase I dose-finding study.

M. Ranson, I. Melezínek, G. Klingelschmitt, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II trial with ISIS 5132 in patients with small-cell (SCLC) and non-small cell (NSCLC) lung cancer. A European Organization for Research and Treatment of Cancer (EORTC) Early Clinical Studies Group report.

M. Borner, J. Smyth, P. Fumoleau, 2001, European journal of cancer.

NET-02: a randomised, non-comparative, phase II trial of nal-IRI/5-FU or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma

J. Cave, Rohini Sharma, D. Cairns, 2023, EClinicalMedicine.

Comparative Kinetics of Immune Responses and Changes in Cellular Sub-Sets Detected in Colorectal Cancer Patients Vaccinated with MVA-5T4 (TroVax) Administered Alongside Two Different Chemotherapy Regimens

R. Hawkins, A. Anthoney, R. Harrop, 2011 .

A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine

R. Plummer, C. Twelves, T. Evans, 2019, British Journal of Cancer.

Abstract CT006: Crizotinib achieves objective responses and long-lasting disease control in patients (pts) with metastatic papillary renal cell carcinoma type 1 (PRCC1) with somaticMETmutations. EORTC phase II trial 90101 “CREATE”

J. Šufliarský, P. Rutkowski, E. Lerut, 2016 .

A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer

R. Plummer, U. Banerji, V. Moreno, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

ESPAC-4: A multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP) versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma: Five year follow-up.

J. Neoptolemos, J. Izbicki, T. Meyer, 2016 .

Single intravenous preoperative administration of the oncolytic virus Pexa-Vec to prime anti-tumor immunity.

A. Melcher, C. Twelves, F. Collinson, 2018 .

Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours

N. Strelkowa, J. Yang, Chih-Hung Hsu, 2020, British Journal of Cancer.

Breast cancer, locally advanced and metastatic

L. Holmberg, O. Nanni, S. Barni, 2012 .

Multicentre phase II pharmacokinetic and pharmacodynamic study of OSI-7904L in previously untreated patients with advanced gastric or gastroesophageal junction adenocarcinoma

J. Ajani, E. Van Cutsem, D. Ferry, 2006, British Journal of Cancer.

M. Büchler, J. Mackey, W. Greenhalf, 2018, British Journal of Cancer.

The effect of erlotinib on CYP3A4 activity, as quantified by the erythromycin breath test and oral midazolam kinetics in cancer patients: Preliminary results

R. Plummer, M. Ranson, C. Twelves, 2005 .

First-in-Human Study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics, and Pharmacodynamics, in Patients with Metastatic Cancer

U. Banerji, J. Spicer, D. Josephs, 2014, Clinical Cancer Research.

Final results from cohort 1 of a phase II study of volociximab, an anti-{alpha}5{beta}1 integrin antibody, in combination with gemcitabine (GEM) in patients (pts) with metastatic pancreatic cancer (MPC)

J. Berlin, R. Glynne-Jones, J. Valle, 2007 .